BACKGROUND: Non-Hodgkin Lymphoma (NHL) is a complicated disease that can result from a number of disease states in addition to typical cancerous processes. There are many treatment options for NHL. Typically, Rituximab, an anti-CD20 monoclonal antibody, has been the mainstay for treatment, either alone or in combination with other treatment options. This review aimed to summarize associated infectious processes and NHL as well as treatment options. METHODS: A systematic review was conducted to determine the treatment options of NHL. This information has been summarized by treatment type. In addition, infectious processes that lead to increased incidence of NHL have also been reviewed and discussed. FINDINGS: The treatment approach varies for each patient and is dependent on type and staging of the disease. There are many singular and combination therapies available for NHL. While Rituximab remains as the first line of treatment for NHL, other drugs and therapy options are being utilized and researched to create even better approaches. Infectious processes have been found to be related to the development of NHL. These include HIV, EBV, HLTV-I, HCV, and others that are still being researched. CONCLUSION: Treatment of NHL is an area that has been extensively researched and is still being studied. Many patients will need subsequent treatment plans following recurrence of NHL, which is why ongoing development and refinement of these therapies is critical. In addition, a better understanding of infectious disease processes that can lead to NHL is very important in prevention and early detection.

Creator

• Phoenix, Inaia

• Heaton, Katelyn

Language

• English

Date created

• 11/9/2018

Resource type

• poster

Source

• mucom_rd_99

Rights statement

• http://rightsstatements.org/vocab/InC/1.0/